To Learn How Different Forms of Study Medicine Are Taken up Into the Blood and the Effect of Food on Study Medicine in Healthy Adults

Pfizer13 enrolled

Overview

The purpose of this study is to learn about the study medicine CTB-AVP for the treatment of severe urinary tract infections that require hospitalization. This study is seeking for: * adult male and female participants who are healthy and weigh more than 50 kg. * participants who have normal blood pressure, normal kidney and liver function * participants willing to stay away from caffeine and other medicines for the duration of the study. Participants will be required to stay in the study clinic for two weeks. All participants in this study will receive study medicine CTB-AVP by mouth one time each day on four different days. Study medicine will be given in capsules or tablets, on an empty stomach or will be taken with a meal. The study will look at the experiences of people receiving the study medicine. This will help determine if the study medicine is safe and effective.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Healthy

Interventions

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Male and female participants aged 18 years or older at screening who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs and standard 12-lead electrocardiogram (ECGs), and with eGFR ≥75 mL/min (estimated using the 2021 CKD-EPI equation). 2. Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. 3. Have a body-mass index (BMI) of 16 to 32 kg/m2; and a total body weight \>50 kg (110 lb). 4. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent document (ICD) and in this protocol. Exclusion Criteria: * Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease; including any condition affecting oral absorption or known allergy to cephalosporin group of antibiotics * Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study intervention or current use of any prohibited concomitant medications. * Screening supine Blood Pressure (BP) ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic) for participants \<60 years; and ≥150/90 mm Hg for participants ≥60 years old, following at least 5 minutes of supine rest * Participants with ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study-specific laboratory and confirmed by a single repeat test, if deemed necessary: alanine aminotransferase (ALT), aspartate aminotransferase (AST), Bilirubin ≥1.5 x Upper Limit of Normal (ULN). Participants with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is ≤ ULN.

Outcomes

Primary Outcomes

Maximum Observed Plasma Concentration [Cmax] of cis-CTB and AVI following test formulation administration in fasted or fed state

Cmax is estimated based on the plasma concentrations for test and reference formulation

Time frame: Through 48 hours in period 1, 2, 3

Dose-normalized Maximum Observed Plasma Concentration [Cmax(dn)] of cis-CTB and AVI following test/ reference formulation administration

Cmax is estimated based on the plasma concentrations for test and reference formulation and then normalized by dose

Time frame: Through 48 hours in period 1, 2, 3

Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of cis-CTB and AVI following test formulation administration in fasted or fed state

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)

Time frame: Through 48 hours in period 1, 2, 3

Dose-Normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUClast(dn)] of cis-CTB and AVI following test/ reference formulation administration

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast) normalized by dose

Time frame: Through 48 hours in period 1, 2, 3

Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of cis-CTB and AVI (if data permit) following test formulation administration in fasted or fed state

AUC (inf)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUClast plus AUClast to infinity.

Time frame: Through 48 hours in period 1, 2, 3

Dose-Normalized Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUCinf(dn)] of cis-CTB and AVI (if data permit) following test/ reference formulation administration

AUC (inf)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUClast plus AUClast to infinity normalized by dose

Time frame: Through 48 hours in period 1, 2, 3

Secondary Outcomes

Number of participants with Treatment Emergent Adverse Events (TEAE)

An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) is defined as any untoward medical occurrence at any dose that results in death; is life threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; results in congenital anomaly/birth defect. AEs include both SAEs and AEs. TEAEs are AEs that occur following the start of treatment or AEs increasing in severity during treatment

Time frame: Time the participant provides informed consent through and including follow-up contact occurring up to 35 days after the last administration of the study intervention

Severity of treatment-emergent adverse events (TEAEs)

Time frame: Time the participant provides informed consent through and including follow-up contact occurring up to 35 days after the last administration of the study intervention

Causal relationship of treatment-emergent adverse events (TEAEs)

Time frame: Time the participant provides informed consent through and including follow-up contact occurring up to 35 days after the last administration of the study intervention

Withdrawals due to treatment-emergent adverse events (TEAEs)

Time frame: Time the participant provides informed consent through and including follow-up contact occurring up to 35 days after the last administration of the study intervention

Number of Participants With Laboratory Abnormalities

Blood samples collected for the analysis of following laboratory parameters: hematology parameters (hemoglobin, erythrocyte mean corpuscular volume, erythrocyte mean corpuscular hemoglobin, erythrocyte mean corpuscular hemoglobin concentration platelet count, leukocytes, lymphocytes, neutrophils, eosinophils, monocytes); clinical chemistry parameters (bilirubin, alanine aminotransferase \[ALT\], blood urea nitrogen \[BUN\], creatinine, potassium, bicarbonate); urine parameters: urine protein, urine hemoglobin, nitrite, leukocyte esterase and bacteria. Number of participants with any laboratory abnormalities is presented.

Number of Participants With Clinically Significant Change From Baseline in Vital Signs

Vital signs evaluation includes: supine systolic and diastolic blood pressure (BP) and pulse rate. Baseline will be the measurement taken on Day -1 and change from baseline (CFB) will be calculated for all post-baseline timepoints, and would be reported as per Sponsor's reporting standards.

Time frame: Time the participant provides informed consent through and including follow-up contact occurring up to 35 days after the last administration of the study intervention

Number of Participants with Clinically Significant Change From Baseline in Electrocardiogram (ECG) Findings

Criteria for clinically significant changes in ECG (12-lead) are defined as: a postdose QTc interval increase by ≥60 msec from the baseline and is \>450 msec; or an absolute QTc value is ≥500 msec for any scheduled ECG

Time frame: Time the participant provides informed consent through and including follow-up contact occurring up to 35 days after the last administration of the study intervention

Terminal Elimination Half-Life (t1/2) (if data permit) of cis-CTB, AVI and HPA

Elimination half-life means the time required for the plasma concentration to decline by 50% during the elimination phase- if data permit

Time frame: Through 48 hours in period 1, 2, 3

Apparent Oral Volume of Distribution (Vz/F) (if data permit) of cis-CTB, AVI and HPA

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug-If data permit

Time frame: Through 48 hours in period 1, 2, 3

Apparent Oral Clearance (CL/F) (if data permit) of cis-CTB, AVI and HPA

Clearance of a drug was measure of the rate at which the drug was metabolized or eliminated by normal biological processes- if data permit

Time frame: Through 48 hours in period 1, 2, 3

To Learn How Different Forms of Study Medicine Are Taken up Into the Blood and the Effect of Food on Study Medicine in Healthy Adults

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes